Definium’s LSD-Based Therapy Wins FDA Breakthrough Status for Depression
Event summary
- Definium Therapeutics' DT120 (lysergide) ODT received FDA Breakthrough Therapy designation for Major Depressive Disorder (MDD) following positive Phase 3 results.
- A single 100 µg dose of DT120 showed an 8.1-point placebo-adjusted improvement in MADRS score at Week 6 (p<0.0001), with durable efficacy through Week 12.
- This is the second Breakthrough Therapy designation for DT120, following its initial designation for Generalized Anxiety Disorder (GAD).
- DT120 is a pharmaceutically optimized formulation of LSD, incorporating Catalent’s Zydis® ODT fast-dissolve technology.
The big picture
Definium’s Breakthrough Therapy designation for DT120 underscores the growing acceptance of psychedelic-based treatments in mainstream psychiatry. With MDD representing a $326 billion annual economic burden in the U.S. and fewer than one-third of patients achieving remission with current treatments, DT120’s potential to offer rapid and durable relief could reshape the mental health treatment landscape. The designation also highlights the FDA’s increasing openness to innovative therapies for serious psychiatric conditions.
What we're watching
- Regulatory Momentum
- Whether the FDA’s Breakthrough Therapy designation will accelerate DT120’s path to market for both MDD and GAD.
- Clinical Validation
- The durability of DT120’s efficacy beyond Week 12 and its potential for long-term remission in MDD patients.
- Market Differentiation
- How DT120’s unique formulation and fast-dissolve technology will position it against existing and emerging psychedelic therapies.